vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Above Fifty Day Moving Average of $18.21

vTv Therapeutics Inc. (NASDAQ:VTVT) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $18.21 and traded as high as $24.96. vTv Therapeutics shares last traded at $24.74, with a volume of 3,423 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, March 14th.

vTv Therapeutics Stock Performance

The company has a fifty day simple moving average of $18.21 and a 200 day simple moving average of $14.46. The stock has a market capitalization of $74.47 million, a price-to-earnings ratio of -2.46 and a beta of 0.56.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Wednesday, March 13th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new stake in shares of vTv Therapeutics during the second quarter worth $30,000. Millennium Management LLC boosted its position in vTv Therapeutics by 12.0% during the second quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 14,845 shares during the last quarter. State Street Corp boosted its position in vTv Therapeutics by 268.7% during the second quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 150,228 shares during the last quarter. Finally, Pathstone Family Office LLC acquired a new stake in vTv Therapeutics during the 3rd quarter worth about $116,000. Institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes that is in Phase III clinical trial; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases, psoriasis, COPD, and Atopic Dermatitis that is in Phase III clinical trial.